Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.40 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.40 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24229708 | 0.85 | HRH3 (0.43) | HRH3HDAC6CYP2D6HRH1CARM1 | |
| SCHEMBL24229699 | 0.79 | HRH3 (0.48) | HRH3HDAC6CYP2D6HRH1 | |
| SCHEMBL24229492 | 0.75 | HRH3 (0.44) | HRH3CYP2D6HRH1CARM1 | |
| SCHEMBL24229635 | 0.74 | HRH3 (0.41) | HRH3CYP2D6HRH1 | |
| SCHEMBL29052790 | 0.74 | HRH3 (0.47) | HRH3CYP2D6HRH1 | |
| SCHEMBL24229758 | 0.74 | HRH3 (0.47) | HRH3CYP2D6HRH1 | |
| SCHEMBL29052789 | 0.73 | HRH3 (0.48) | HRH3CYP2D6HRH1CARM1 | |
| SCHEMBL5450398 | 0.72 | HRH3 (1.00) | HRH3CYP2D6HRH1NPC1RAB9A | |
| SCHEMBL29474881 | 0.72 | HRH3 (0.70) | HRH3CYP2D6HRH1CARM1CHRNA7 | |
| SCHEMBL24229756 | 0.71 | HDAC6 (0.56) | HRH3HDAC6CYP2D6HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858930-B2 | Fused bicyclic RAF inhibitors and methods for use thereof | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2024-01-02 | — | — | US | disclosed |
| US-11858930-B2 | Fused bicyclic RAF inhibitors and methods for use thereof | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2024-01-02 | — | — | US | disclosed |
| WO-2022023447-A2 | FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2022-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858930-B2 | Fused bicyclic RAF inhibitors and methods for use thereof | BRAF, RAF1, NRAS | HRH3 3556/4885HDAC6 948/4885CYP2D6 2672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.